Insider Selling: Orthofix Medical (NASDAQ:OFIX) CFO Sells $70,073.74 in Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CFO Julie Andrews sold 4,873 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $14.38, for a total value of $70,073.74. Following the sale, the chief financial officer owned 58,039 shares of the company’s stock, valued at approximately $834,600.82. This represents a 7.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Orthofix Medical Price Performance

Shares of NASDAQ OFIX opened at $13.33 on Friday. The firm has a market cap of $527.87 million, a P/E ratio of -4.40 and a beta of 0.79. The business’s 50 day moving average is $15.21 and its 200-day moving average is $14.37. The company has a current ratio of 2.47, a quick ratio of 1.38 and a debt-to-equity ratio of 0.39. Orthofix Medical Inc. has a 1-year low of $10.24 and a 1-year high of $20.48.

Institutional Trading of Orthofix Medical

A number of institutional investors and hedge funds have recently made changes to their positions in OFIX. CWM LLC boosted its position in shares of Orthofix Medical by 99.0% during the 3rd quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock worth $28,000 after acquiring an additional 955 shares in the last quarter. Raymond James Financial Inc. lifted its stake in Orthofix Medical by 1.5% during the third quarter. Raymond James Financial Inc. now owns 66,812 shares of the medical device company’s stock worth $978,000 after purchasing an additional 1,000 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Orthofix Medical by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock valued at $335,000 after purchasing an additional 1,213 shares in the last quarter. Monaco Asset Management SAM boosted its holdings in shares of Orthofix Medical by 3.0% in the 3rd quarter. Monaco Asset Management SAM now owns 58,059 shares of the medical device company’s stock valued at $850,000 after purchasing an additional 1,690 shares in the last quarter. Finally, State of Alaska Department of Revenue acquired a new position in shares of Orthofix Medical during the 3rd quarter worth $30,000. Institutional investors own 89.76% of the company’s stock.

Analyst Upgrades and Downgrades

OFIX has been the topic of a number of recent research reports. Stifel Nicolaus started coverage on shares of Orthofix Medical in a research report on Tuesday, October 28th. They set a “buy” rating and a $22.00 price target on the stock. Barrington Research raised their target price on shares of Orthofix Medical from $17.00 to $18.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a research note on Thursday. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $21.50.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.